CUPERTINO, Calif., Dec. 11 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it has successfully completed Phase I
clinical trials with a new product, DUR-843, which is intended to treat a
persistent pain condition. We believe that the persistent pain market remains
underserved and that DUR-843 has the potential to provide several advantages
over existing pain medications.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
“We are pleased to add another product candidate to our pipeline and with
the rapid progress and positive results thus far,” stated James E. Brown, DVM,
President and CEO of DURECT. “As a result of our recent collaboration with
Nycomed covering POSIDUR, we are in a stronger financial position and
therefore have decided to further develop this product on our own as part of
our strategy to become a specialty pharmaceutical company. To that
objective, for competitive reasons, DURECT is not disclosing at this time the
specific drug delivery technology which underlies DUR-843 as well as the
active pharmaceutical agent.”
The objectives of the Phase I clinical studies recently completed were to
determine the safety and tolerability of DUR-843 in healthy human volunteers
as well as evaluate the pharmacokinetics of the active pharmaceutical agent
following administration of the product candidate. In these trials, DUR-843
appeared safe and well-tolerated.
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies focused on treating chronic and episodic
diseases and conditions. The Company currently has a number of late-stage
pharmaceutical products in development initially focused on significant unmet
medical needs in pain management, with a number of research programs underway
in a variety of other therapeutic areas. For more information, please visit
www.www.durect.com.
NOTE: DUR-843 is a drug candidate under development and has not been
submitted or approved for commercialization by the US Food and Drug
Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in this press release regarding DURECT’s product candidate
DUR-843, its attributes and commercial potential are forward-looking
statements involving risks and uncertainties that can cause actual results to
differ materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, DURECT’s ability to
design, enroll, conduct and complete clinical trials, complete the design,
development, and manufacturing process development of the product candidate,
obtain product and manufacturing approvals from regulatory agencies and
manufacture and commercialize the product candidate, as well as marketplace
acceptance of the product candidate. Further information regarding these and
other risks is included in DURECT’s Form 10-Q dated November 3, 2006 under the
heading “Risk Factors.”
SOURCE DURECT Corporation
12/11/2006
CONTACT: Schond L. Greenway, Vice President, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417; or Media Contact:
Jeremiah Hall, Senior Vice President of Feinstein Kean Healthcare,
+1-415-677-2700 or jeremiah.hall@fkhealth.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.www.durect.com
(DRRX)